AIMS: With ongoing efforts to target the epidermal growth factor receptor (EGFR)-mediated tumour growth in the treatment of selected human malignancies, there is a need to determine the expression levels of EGFR and to evaluate its prognostic value in various malignancies in the Asia-Pacific region. METHODS AND RESULTS: A total of 172 patients with head and neck squamous cell carcinomas from Australia, Hong Kong, Singapore, and Taiwan were selected for EGFR detection. Immunohistochemical staining was performed to evaluate EGFR expression. EGFR expression was present in 88.4% (152/172) of all cases tested. Specifically, EGFR expression was found in 91.3% (42/46), 84.6% (22/26), 84.1% (37/44), 96.0% (24/25), and 87.1% (27/31) cases of head and neck squamous cell carcinomas from the oral cavity, oropharynx, nasopharynx, hypopharynx, and larynx, respectively. The results demonstrate a stronger EGFR expression in T4 tumours (P=0.017) and later clinical stages (P=0.016). No significant correlation was seen with risk factors, primary tumour site and ethnicity. CONCLUSIONS: The majority of head and neck squamous cell carcinomas express EGFR, indicating the importance of studying the efficacy of anti-cancer therapy through this pathway. The results also show similar rates of receptor expression in head and neck squamous cell carcinoma patients from our region compared with other parts of the world.
AIMS: With ongoing efforts to target the epidermal growth factor receptor (EGFR)-mediated tumour growth in the treatment of selected humanmalignancies, there is a need to determine the expression levels of EGFR and to evaluate its prognostic value in various malignancies in the Asia-Pacific region. METHODS AND RESULTS: A total of 172 patients with head and neck squamous cell carcinomas from Australia, Hong Kong, Singapore, and Taiwan were selected for EGFR detection. Immunohistochemical staining was performed to evaluate EGFR expression. EGFR expression was present in 88.4% (152/172) of all cases tested. Specifically, EGFR expression was found in 91.3% (42/46), 84.6% (22/26), 84.1% (37/44), 96.0% (24/25), and 87.1% (27/31) cases of head and neck squamous cell carcinomas from the oral cavity, oropharynx, nasopharynx, hypopharynx, and larynx, respectively. The results demonstrate a stronger EGFR expression in T4 tumours (P=0.017) and later clinical stages (P=0.016). No significant correlation was seen with risk factors, primary tumour site and ethnicity. CONCLUSIONS: The majority of head and neck squamous cell carcinomas express EGFR, indicating the importance of studying the efficacy of anti-cancer therapy through this pathway. The results also show similar rates of receptor expression in head and neck squamous cell carcinomapatients from our region compared with other parts of the world.
Authors: Mitchell J Frederick; Amy J VanMeter; Mayur A Gadhikar; Ying C Henderson; Hui Yao; Curtis C Pickering; Michelle D Williams; Adel K El-Naggar; Vlad Sandulache; Emily Tarco; Jeffrey N Myers; Gary L Clayman; Lance A Liotta; Emanuel F Petricoin; Valerie S Calvert; Valentina Fodale; Jing Wang; Randal S Weber Journal: Am J Pathol Date: 2011-02 Impact factor: 4.307
Authors: Xiu Juan Cao; Jun Fang Hao; Xin Hua Yang; Peng Xie; Lan Ping Liu; Chun Ping Yao; Jin Xu Journal: Med Oncol Date: 2011-01-08 Impact factor: 3.064
Authors: Monica Charlotte Solomon; M S Vidyasagar; Donald Fernandes; Vasudev Guddattu; Mary Mathew; Ankur Kaur Shergill; Sunitha Carnelio; Chetana Chandrashekar Journal: Med Oncol Date: 2016-11-05 Impact factor: 3.064
Authors: Ramesh K Wali; Dhananjay P Kunte; Mart De La Cruz; Ashish K Tiwari; Jeffrey Brasky; Christopher R Weber; Tina P Gibson; Amir Patel; Suzana D Savkovic; Bruce E Brockstein; Hemant K Roy Journal: PLoS One Date: 2012-06-04 Impact factor: 3.240
Authors: Christina Magkou; Lydia Nakopoulou; Christina Zoubouli; Kanelina Karali; Irene Theohari; Panagiotis Bakarakos; Ioanna Giannopoulou Journal: Breast Cancer Res Date: 2008-06-03 Impact factor: 6.466